Renal safety of tenofovir in HIV treatment-experienced patients
Authors:
- Corinne Isnard-BagnisCICorinne Isnard-Bagnis
- Jean- Sébastien HulotJHJean- Sébastien Hulot
- Daniel VittecoqDVDaniel Vittecoq
- Andrew ChengACAndrew Cheng
- Carmen Kreft JaisCJCarmen Kreft Jais
- Vincent Launay-VacherVLVincent Launay-Vacher
- Gilbert DerayGDGilbert Deray
- 1 April 2004
- journal article
- clinical trial
- Published by Wolters Kluwer Health in AIDS
- Vol. 18 (7) , 1074-1076
Abstract
The safety of tenovir disoproxil fumarate (TDF) was assessed in two double-blind, placebo-controlled studies. Furthermore, we retrospectively collected 19 cases of TDF-associated tubular dysfunction. The incidence of renal events was similar among the active TDF groups and the placebo group in the two double-blind, placebo-controlled studies. Proximal tubulopathy was diagnosed 6.89 +/- 5.51 months after TDF therapy started. All abnormalities normalized within 4.7 +/- 2.94 weeks after drug discontinuation.Keywords
This publication has 8 references indexed in Scilit:
- Development of Proteinuria or Elevated Serum Creatinine and Mortality in HIV-Infected WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Long-Term Renal Effects of Low-Dose Cyclosporine in Uveitis-Treated PatientsJournal of the American Society of Nephrology, 2002
- Rapid Communication: Acute Renal Failure Associated with Tenofovir: Evidence of Drug-Induced NephrotoxicityThe American Journal of the Medical Sciences, 2002
- Fanconi syndrome and renal failure induced by tenofovir: A first case reportAmerican Journal of Kidney Diseases, 2002
- Predictors of proteinuria and renal failure among women with HIV infectionKidney International, 2002
- Pattern of glomerular involvement in human immunodeficiency virus—infected patients: An Italian studyAmerican Journal of Kidney Diseases, 1995
- Electrolyte and acid-base disorders associated with AIDSJournal of General Internal Medicine, 1994
- HIV-associated immune-mediated renal diseaseKidney International, 1993